Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 711-720

  Gravina, Giovanni Luca ^a   Marampon, Francesco ^a   Giusti, Ilaria ^a   Carosa, Eleonora ^a   Di Sante, Stefania ^a   Ricevuto, Enrico ^a   Dolo, Vincenza ^a   Tombolini, Vincenzo ^b   Jannini, Emmanuele A ^a   Festuccia, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Belinostat; Epigenetic; Histone deacetylation; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BELINOSTAT; CASPASE 8; CASPASE 9; HISTONE DEACETYLASE INHIBITOR; P21 ACTIVATED KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; SODIUM CHLORIDE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HISTONE ACETYLATION; HORMONE DEPENDENCE; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

ACETYLATION; ANDROGENS; ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857145666     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1270     Document Type: Article

References (37)

1. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N and Sawyers CL: Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69: 958-966, 2009.
2. Cress WD and Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1-16, 2000. (Pubitemid 30349623)
3. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I and Lee P: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1: 62-71, 2009.
4. Patra SK, Patra A and Dahiya R: Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287: 705-713, 2001. (Pubitemid 32912772)
5. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189, 2004. (Pubitemid 38481229)
6. Halkidou K, Cook S, Leung HY, Neal DE and Robson CN: Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 45: 382-389, 2004. (Pubitemid 38221414)
7. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W and Verdin E: Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9: 45-57, 2002. (Pubitemid 34127770)
8. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS and Sehested M: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589, 2008. (Pubitemid 351184977)
9. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB and Brown R: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728, 2003.
10. Qian X, La Rochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS and Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5: 2086-2095, 2006. (Pubitemid 44336581)
11. Duan J, Friedman J, Nottingham L, Chen Z, Ara G and van Waes C: Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6: 37-50, 2007. (Pubitemid 46206667)
12. Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M and Ritchie JW: The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer growth in vitro and in vivo. Cancer Chemother Pharmacol 60: 275-283, 2007. (Pubitemid 46742543)
13. Prince HM, Bishton MJ and Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969, 2009.
14. Tepper CG, Boucher DL, Ryan PE, et al: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614, 2002. (Pubitemid 35364127)
15. Craft N, Shostak Y, Carey M, et al: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-286, 1999.
16. Karan D, Kelly DL, Rizzino A, Lin MF and Batra SK: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23: 967-972, 2002.
17. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD and Keller ET: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47: 212-221, 2001. (Pubitemid 32378373)
18. Zhao H, Dupont J, Yakar S, et al: PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23: 786-794, 2004. (Pubitemid 38241279)
19. Bonaccorsi L, Carloni V, Muratori M, et al: Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 141: 3172-3176, 2000.
20. Scaccianoce E, Festuccia C, Dondi D, et al: Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 14: 101-112, 2003. (Pubitemid 38166339)
21. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL and Pienta KJ: VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163-168, 2001.
22. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, van Dyke TA, Weber MJ, Wu L and Vessella RL: The current state of preclinical prostate cancer animal models. Prostate 68: 629-639, 2008. (Pubitemid 351614641)
23. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003, 2002. (Pubitemid 34517632)
24. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P and Budillon A: Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12: 617-625, 2006. (Pubitemid 43166157)
25. Gravina G, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V and Festuccia C: The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone refractory prostate cancer cells. Endocr Relat Cancer (In press).
26. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ and Huang J: PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (In press).
27. Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Tatsugami K, Inokuchi J, Takeuchi A and Naito S: Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 71: 298-304, 2011.
28. Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z and Nudelman A: In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer 116: 226-235, 2005. (Pubitemid 40967259)
29. Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, Carducci M and Rodriguez R: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006. (Pubitemid 44197704)
30. Kumar R, Wang RA and Bagheri-Yarmand R: Emerging roles of MTA family members in human cancers. Semin Oncol 30: 30-37, 2003. (Pubitemid 37433394)
31. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG and Baek SH: Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434: 921-926, 2005. (Pubitemid 40559007)
32. Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281: 5612-5622, 2006. (Pubitemid 43847658)
33. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC and Rees RC: DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68: 210-222, 2008. (Pubitemid 351186233)
34. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L and Pili R: Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67: 1182-1193, 2007. (Pubitemid 47221885)
35. Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW and Alaoui-Jamali MA: A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate 66: 1151-1161, 2006. (Pubitemid 44175338)
36. Gravina GL, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V and Festuccia C: Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol 35: 1133-1139, 2009.
37. Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM and Fulda S: Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28: 3097-3110, 2009.